Smith & Nephew shares drop 9% as US knee implant sales lag

Shares of Smith & Nephew fell nearly 9% on Thursday after the British medical products maker missed analyst estimates for quarterly revenue due to weakness in its U.S. knee implants business.
Seeking Alpha

Smith & Nephew: Work To Be Done But Still Long-Term Potential

Smith & Nephew's share price has increased by 14% since September 2022, indicating undervaluation. The company showed decent top line growth with a 6.4% increase in revenue last year. While the ...
FierceBiotech

Smith+Nephew swoops in with $330M offer for CartiHeal after Bioventus bows out

After the collapse of Bioventus’ efforts to acquire its previous orthopedic partner CartiHeal last year, Smith+Nephew has swooped in to pick up the sports medicine developer—and at a discount. The ...

Smith+Nephew beats estimates as elective surgeries bounce back

British medical devices maker Smith+Nephew topped expectations for first-quarter sales on Thursday, buoyed by a rebound in elective surgeries and robust demand for its products.
Forbes

Smith & Nephew Shares Leap 9% As Restructuring Drives Profits Higher

Shares in medical firm Smith & Nephew leapt on Tuesday as ongoing restructuring delivered strong full-year sales and profits. At £11.37 per share, Smith & Nephew’s share price was 9% higher on the day ...